Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 25

1.

A normal genetic variation modulates synaptic MMP-9 protein levels and the severity of schizophrenia symptoms.

Lepeta K, Purzycka KJ, Pachulska-Wieczorek K, Mitjans M, Begemann M, Vafadari B, Bijata K, Adamiak RW, Ehrenreich H, Dziembowska M, Kaczmarek L.

EMBO Mol Med. 2017 Aug;9(8):1100-1116. doi: 10.15252/emmm.201707723.

2.

Blood assessment of the expression levels of matrix metalloproteinase 9 (MMP9) and its natural inhibitor, TIMP1 genes in Iranian schizophrenic patients.

Rahimi S, Sayad A, Moslemi E, Ghafouri-Fard S, Taheri M.

Metab Brain Dis. 2017 Oct;32(5):1537-1542. doi: 10.1007/s11011-017-0043-z. Epub 2017 Jun 4.

PMID:
28578515
3.

Redox dysregulation, immuno-inflammatory alterations and genetic variants of BDNF and MMP-9 in schizophrenia: Pathophysiological and phenotypic implications.

Ali FT, Abd El-Azeem EM, Hamed MA, Ali MAM, Abd Al-Kader NM, Hassan EA.

Schizophr Res. 2017 Oct;188:98-109. doi: 10.1016/j.schres.2017.01.016. Epub 2017 Jan 15.

PMID:
28100419
4.

Blood-brain barrier and intestinal epithelial barrier alterations in autism spectrum disorders.

Fiorentino M, Sapone A, Senger S, Camhi SS, Kadzielski SM, Buie TM, Kelly DL, Cascella N, Fasano A.

Mol Autism. 2016 Nov 29;7:49. eCollection 2016.

5.

MMP-9 in translation: from molecule to brain physiology, pathology, and therapy.

Vafadari B, Salamian A, Kaczmarek L.

J Neurochem. 2016 Oct;139 Suppl 2:91-114. doi: 10.1111/jnc.13415. Epub 2016 Mar 21. Review.

6.

MMP-9 Serum Levels in Schizophrenic Patients during Treatment Augmentation with Sarcosine (Results of the PULSAR Study).

Strzelecki D, Kałużyńska O, Szyburska J, Wysokiński A.

Int J Mol Sci. 2016 Jul 9;17(7). pii: E1075. doi: 10.3390/ijms17071075.

7.

Altered Serum Levels of Matrix Metalloproteinase-2, -9 in Response to Electroconvulsive Therapy for Mood Disorders.

Shibasaki C, Takebayashi M, Itagaki K, Abe H, Kajitani N, Okada-Tsuchioka M, Yamawaki S.

Int J Neuropsychopharmacol. 2016 Aug 31;19(9). pii: pyw019. doi: 10.1093/ijnp/pyw019. Print 2016 Sep.

8.

CHRNA7 inhibits cell invasion and metastasis of LoVo human colorectal cancer cells through PI3K/Akt signaling.

Xiang T, Yu F, Fei R, Qian J, Chen W.

Oncol Rep. 2016 Feb;35(2):999-1005. doi: 10.3892/or.2015.4462. Epub 2015 Nov 27.

PMID:
26719016
9.

Lipoid proteinosis.

Mcgrath JA.

Handb Clin Neurol. 2015;132:317-22. doi: 10.1016/B978-0-444-62702-5.00023-8. Review.

PMID:
26564090
10.

Relationship between matrix metalloproteinase-9 and oxidative stress in drug-free male schizophrenia: a case control study.

Devanarayanan S, Nandeesha H, Kattimani S, Sarkar S.

Clin Chem Lab Med. 2016 Mar;54(3):447-52. doi: 10.1515/cclm-2015-0212.

PMID:
26351924
11.

The Schizophrenia-Related Protein Dysbindin-1A Is Degraded and Facilitates NF-Kappa B Activity in the Nucleus.

Fu C, Chen D, Chen R, Hu Q, Wang G.

PLoS One. 2015 Jul 14;10(7):e0132639. doi: 10.1371/journal.pone.0132639. eCollection 2015.

12.

Functional polymorphism of matrix metalloproteinase-9 (MMP9) gene is not associated with schizophrenia and with its deficit subtype.

Bienkowski P, Samochowiec J, Pelka-Wysiecka J, Grzywacz A, Skibinska M, Jasiewicz A, Tybura P, Wroński M, Jarema M, Samochowiec A.

Pharmacol Rep. 2015 Jun;67(3):442-5. doi: 10.1016/j.pharep.2014.11.007. Epub 2014 Nov 27.

PMID:
25933951
13.

Matrix Metalloproteinase-9 as a Novel Player in Synaptic Plasticity and Schizophrenia.

Lepeta K, Kaczmarek L.

Schizophr Bull. 2015 Sep;41(5):1003-9. doi: 10.1093/schbul/sbv036. Epub 2015 Apr 2. Review.

14.

A positive correlation between serum levels of mature brain-derived neurotrophic factor and negative symptoms in schizophrenia.

Niitsu T, Ishima T, Yoshida T, Hashimoto T, Matsuzawa D, Shirayama Y, Nakazato M, Shimizu E, Hashimoto K, Iyo M.

Psychiatry Res. 2014 Feb 28;215(2):268-73. doi: 10.1016/j.psychres.2013.12.009. Epub 2013 Dec 14.

PMID:
24377440
15.

Plasma levels of mature brain-derived neurotrophic factor (BDNF) and matrix metalloproteinase-9 (MMP-9) in treatment-resistant schizophrenia treated with clozapine.

Yamamori H, Hashimoto R, Ishima T, Kishi F, Yasuda Y, Ohi K, Fujimoto M, Umeda-Yano S, Ito A, Hashimoto K, Takeda M.

Neurosci Lett. 2013 Nov 27;556:37-41. doi: 10.1016/j.neulet.2013.09.059. Epub 2013 Oct 18.

16.

Increased serum matrix metalloproteinase-9 (MMP-9) levels in young patients during bipolar depression.

Rybakowski JK, Remlinger-Molenda A, Czech-Kucharska A, Wojcicka M, Michalak M, Losy J.

J Affect Disord. 2013 Apr 5;146(2):286-9. doi: 10.1016/j.jad.2012.07.019. Epub 2012 Aug 2.

PMID:
22858217
17.

[Family based association study of MMP-9 gene-1562C>T polymorphism in schizophrenia].

Groszewska A, Kapelski P, Skibińska M, Hauser J.

Psychiatr Pol. 2011 May-Jun;45(3):317-24. Polish.

PMID:
22232962
18.

The C(-1562)T polymorphism of matrix metalloproteinase-9 gene is associated with schizophrenia in China.

Han H, He X, Tang J, Liu W, Liu K, Zhang J, Wang X, Xu Y, Chen X.

Psychiatry Res. 2011 Nov 30;190(1):163-4. doi: 10.1016/j.psychres.2011.04.026. Epub 2011 May 26. No abstract available.

PMID:
21620482
19.

Functional polymorphism of matrix metalloproteinase-9 (MMP-9) gene and response to lithium prophylaxis in bipolar patients.

Rybakowski JK, Skibinska M, Suwalska A, Leszczynska-Rodziewicz A, Kaczmarek L, Hauser J.

Hum Psychopharmacol. 2011 Mar;26(2):168-71. doi: 10.1002/hup.1182. Epub 2011 Mar 16.

PMID:
21437990
20.

Expression of anti-cardiolipin antibodies and inflammatory associated factors in patients with schizophrenia.

Chang SH, Chiang SY, Chiu CC, Tsai CC, Tsai HH, Huang CY, Hsu TC, Tzang BS.

Psychiatry Res. 2011 May 30;187(3):341-6. doi: 10.1016/j.psychres.2010.04.049. Epub 2010 May 26.

PMID:
20510460

Supplemental Content

Loading ...
Support Center